Skip to main content

Table 4 Univariate and multivariate analysis for overall survival (OS) and disease-free survival (DFS)

From: Elevated HOXA1 expression correlates with accelerated tumor cell proliferation and poor prognosis in gastric cancer partly via cyclin D1

 

OS

DFS

 

Univariate

 

Multivariate

 

Univariate

 

Multivariate

 

Variable

HR (95 % CI)

P value

HR (95 % CI)

P value

HR (95 % CI)

P value

HR (95 % CI)

P value

HOXA1/cyclin D1

        

 Both negative

1

 

1

 

1

 

1

 

 One positive

1.623(0.643-4.099)

0.305

1.800(0.702-4.615)

0.221

1.577(0.625-3.983)

0.335

1.674(0.652-4.297)

0.284

 Both positive

9.064(4.278-19.203)

<0.001*

9.905(4.453-22.031)

<0.001*

8.495(4.021-17.948)

<0.001*

8.636(3.916-19.047)

<0.001*

HOXA1

        

 Negative

1

   

1

   

 Positive

4.601(2.504-8.454)

<0.001*

  

4.438(2.418-8.145)

<0.001*

  

Cyclin D1

        

 Negative

1

   

1

   

 Positive

5.893(3.159-10.990)

<0.001*

  

5.673(3.044-10.572)

<0.001*

  

Age(years)

        

 <65

1

   

1

 

1

 

 ≥65

1.880(1.103-3.202)

0.020*

  

1.862(1.093-3.172)

0.022*

1.738(1.011-2.987)

0.046*

Gender

        

 Male

1

   

‒

   

 Female

1.002(0.603-1.666)

0.992

  

1.006(0.605-1.671)

0.982

  

T stage

        

 T1

1

   

1

   

 T2

2.787(0.786-9.885)

0.113

  

2.871(0.809-10.183)

0.103

  

 T3

7.596(2.709-21.302)

<0.001*

  

7.543(2.690-21.150)

<0.001*

  

 T4

12.061(3.928-37.036)

<0.001*

  

12.200(3.973-37.465)

<0.001*

  

N stage

        

 N0

1

   

1

   

 N1

4.023(1.799-8.999)

0.001*

  

4.048(1.810-9.054)

0.001*

  

 N2

9.647(4.238-21.959)

<0.001*

  

9.489(4.170-21.592)

<0.001*

  

 N3

16.913(6.668-42.899)

<0.001*

  

18.152(7.149-46.088)

<0.001*

  

M stage

        

 M0

1

   

1

   

 M1

3.082(1.232-7.709)

0.016*

  

3.405(1.361-8.518)

0.009*

  

UICC stage

        

 I

1

 

1

 

1

 

1

 

 II

6.795(1.869-24.701)

0.004*

8.168(2.241-29.773)

0.001*

6.867(1.889-24.962)

0.003*

7.172(1.961-26.222)

0.003*

 III

13.458(4.100-44.180)

<0.001*

14.327(4.325-47.457)

<0.001*

13.355(4.069-43.834)

<0.001*

12.571(3.791-41.678)

<0.001*

 IV

32.066(9.433-109.001)

<0.001*

30.392(8.750-105.567)

<0.001*

34.583(10.172-117.570)

<0.001*

33.649(9.676-117.020)

<0.001*

Differentiation

        

 High

1

   

1

   

 Moderate

5.441(1.155-25.634)

0.032*

  

5.499(1.167-25.909)

0.031*

  

 Low

8.506(2.070-34.961)

0.003*

  

8.581(2.088-35.268)

0.003*

  
  1. HR hazard ratio; CI confidence interval
  2. *P < 0.05 indicates that the 95 % CI of the HR did not include 1
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us